The support given to the patients included medication, prostheses, transportation, and food, the institution announced.

According to data released by the League, 25,200 patients were supported last year, 3,300 more (15%) than in 2024, and €2.2 million more was allocated in support, representing a 24% increase.

This increase emphasises that "reflects the growing demand for support from patients and the LPCC's ability to respond to them."

Investing in research

Regarding research and training in Oncology, the Portuguese League Against Cancer (LPCC) invested €700,000, double the amount recorded in the previous year. This amount funded 38 research grants and 4 research centres, as well as training for 1,810 healthcare professionals.

This growth extended to virtually all of the LPCC's responses and interventions: in 2025, 21,300 free psycho-oncology consultations were provided, serving nearly 3,700 patients.

In the area of ​​prevention, there were 14,537 consultations for early diagnosis of skin and oral cancer, along with smoking cessation and nutrition consultations.

Patient follow-up

Throughout the year, more than 8,200 patients were followed up in day centres and about 400 in homes, says the League, adding that the Cancer and Lung Hotlines registered more than 6,000 contacts, including calls and emails.

"The growth of LPCC's activity was accompanied by the involvement of approximately 21,700 volunteers, ensuring, with their commitment and solidarity, the LPCC's proximity to patients and families," he emphasises.

Reinforced investment

The president of LPCC, Vítor Veloso, highlights that the institution reached more people last year and reinforced its investment in cancer research.

"This mission is only possible thanks to the contribution of collaborators, volunteers and the generosity of civil society. Every contribution is fundamental so that we can be by the side of those who need it most, every day," says Vítor Veloso, quoted in the statement.

LPCC's mission also includes defending the rights of cancer patients and survivors, representing them before relevant authorities, and promoting policies that ensure their protection, access to information, and support throughout the course of the disease.